CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

SC1911_Scientist_1249633780_1200.jpg
Histology readings showed unexpected safety signals in CymaBay's Phase IIb NASH trial
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D